-Reuters
Jefferies Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $75
Jefferies analyst Maury Raycroft maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $92 to $75.
Related Posts
Mid-Afternoon Market Update: Dow Turns Positive; Snap Shares Climb Following Upbeat Results
The Dow Jones turned higher later in the session on Friday following upbeat earnings from Amazon.com, Inc. (NASDAQ: AMZN) and strong payrolls report for January.
Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results
Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results.
Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s quarterly sales came in at $49.41 million, versus estimates of $97.30 million.
Fannie Mae, Freddie Mac Shares Nosedive After Supreme Court Rejects Investors’ Claims
Shares of Fannie Mae (OTC: FNMA) and Freddie Mac (OTC: FMCC) went into a tailspin after the U.S.